News | October 30, 2024
GlaxoSmithKline Pharmaceuticals Q2 FY25 revenue crosses Rs. 1,000 Cr
The Pediatric vaccine portfolio delivered double-digit growth and maintained its market leadership in the private market
The Pediatric vaccine portfolio delivered double-digit growth and maintained its market leadership in the private market
Product basket comprises 2,047 medicines and 300 surgical devices covering all major therapeutic groups
Spread over 1.26 lakh sq ft building, the super-specialty eye hospital will perform 30,000 free eye surgeries annually for economically weaker sections
The share subscription agreements are being executed at a pre-money equity value of US$ 1.65 billion
The special financing terms offered by United Imaging and structured by Medikabazaar to Krsnaa Diagnostics underscore the strategic importance of this alliance
Doses will be ready to ship to applicable European Union (EU) member states as soon as possible upon European Commission (EC) authorization
The exclusive hospital will help address health complexities concerning women and children, specializing in high-end obstetrics, comprehensive gynecological, neonatal & pediatric care
Total investment incurred for setting up the new R&D Rs 250 crore
Lilly will license certain baricitinib manufacturing know-how to enable EVA Pharma to manufacture and supply treatment for various immunological diseases
Multi-year collaboration focuses on development of biodegradable antimicrobial peptides with broad application possibilities in the areas of skin care and healthcare
Subscribe To Our Newsletter & Stay Updated
